GlassScriptPhysician profile
Rana K Munna
NPI 1053339168
$1,490.06
in general payments reported to CMS, 2019-2025
15 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2021: $218 · 2022: $200 · 2023: $297 · 2024: $207 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $550.64 | 2019-2023 | Farxiga |
| Amgen INC. | $196.17 | 2019-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $123.12 | 2024 | Spravato |
| Abbvie INC. | $118.26 | 2021-2025 | |
| Pfizer INC. | $108.84 | 2019-2024 | |
| Axsome Therapeutics, INC. | $100.93 | 2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $74.86 | 2022 | |
| Lilly USA, LLC | $56.89 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $40.87 | 2021-2025 | Gardasil 9, Capvaxive |
| Novo Nordisk INC | $38.95 | 2021-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.35 | 2022 | |
| Dexcom, INC. | $16.69 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $13.80 | 2022 | |
| Medtronic USA, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rana Munna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.